Completed PHASE2 INTERVENTIONAL 2-arm NCT00523718

Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder

A Double-blind Study of Riluzole Augmentation in Serotonin Reuptake Inhibitor-refractory Obsessive-compulsive Disorder and Depression

Sponsor: National Institute of Mental Health (NIMH)

Conditions Obsessive-compulsive Disorder Ocd

Interventions placebo riluzole

Updated 6 times since 2017 Last updated: Mar 4, 2020 Started: Sep 30, 2006 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00523718, this PHASE2 trial focuses on Obsessive-compulsive Disorder and Ocd and remains completed. Sponsored by National Institute of Mental Health (NIMH), it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Apr 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Apr 2020 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States